ESMO recommendations for the application of hematopoietic growth factors.
Greil
R
R
University Hospital Salzburg, Dept of Hematology/Oncology, Muellnerhauptstrasse 48, 5020 Salzburg, Austria.
Jost
L M
LM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012307:Risk Factors; D033581:Stem Cell Transplantation
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim